Effect of smoking reduction and cessation on cardiovascular risk factors

Nicotine and Tobacco Research

Volumn 3, Issue 3, 2001, Pages 249-255

  Eliasson, B ^a   Hjalmarson, A ^a   Kruse, E ^a   Landfeldt, B ^a   Westin, A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINE; NOSE SPRAY; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HEMATOCRIT; HUMAN; LEUKOCYTE; MALE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TIME; TOBACCO;

EID: 0034852215     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200110050510     Document Type: Article

References (56)

1. Snuff, nicotine and cardiovascular disease: Implications for tobacco control
2. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy
3. Influence of smoking fewer cigarettes on exposure to tar, nicotine and carbon monoxide
4. Suppression of nicotine intake during ad libitum smoking by high-dose transdermal nicotine
5. A randomised clinical trial evaluating the efficacy and safety of an oral nicotine inhaler in achieving smoking reduction
6. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens
7. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies
8. White blood cell count as a predictor of mortality: Results over 18 years from the Normative Aging Study
9. The process of smoking cessation: An analysis of precontemplation, contemplation, and preparation stages of change
10. Mortality in relation to smoking: 40 years' observation on male British doctors
11. Leucocytes and the risk of ischemic diseases
12. Distributions of smokers by stage: International comparison and association with smoking prevalence
13. Nicotine dependence versus prevalence of smoking: Comparison between countries and categories of smokers
14. Aiding reduction of smoking with nicotine replacement medications: Hope for the recalcitrant smoker?
15. Effect of transdermal nicotine patches on cigarette smoking: A double-blind crossover study
16. Controlled smoking, with or without carbon monoxide feedback, as an alternative for chronic smokers
17. Long-term effects of a controlled smoking program: A 2 1/2 year follow-up
18. Prognostic importance of the white cell count for coronary, cancer and all-cause mortality
19. Fibrinogen as a risk factor in cardiovascular disease
20. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire
21. Introduction to tobacco harm reduction as a complementary strategy to smoking cessation
22. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study
23. An analysis of randomised trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
24. Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine during exercise
25. Four beliefs that may impede progress in the treatment of smoking
26. Applying harm reduction to smoking
27. Ability of smokers to reduce their smoking and its association with future smoking cessation
28. Nicotine replacement: A new approach to reducing tobacco-related harm
29. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
30. Fibrinogen and risk of cardiovascular disease: The Framingham Study
31. White blood cell count and cardiovascular disease. Insights from the Framingham Study
32. Harm reduction: The possible role of nicotine replacement
33. Measuring the health hazards of tobacco
34. Method for determining thiocyanate in serum and urine
35. The health consequences of smoking: Cardiovascular diseases
36. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia
37. Effects of changes in smoking and other characteristics of clotting factors and the risk of ischaemic heart disease
38. Mortality and morbidity from smoking-induced cardiovascular diseases
39. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study
40. Smoking habits in relapsed subjects from a smoking cessation trial after one year
41. Rethinking stop-smoking medications: Myths and facts
42. Transdermal nicotine: Reduction of smoking with minimal abuse liability
43. Fibrinogen and carboxyhaemoglobin in peripheral arterial disease
44. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers
45. Cigarette smoking and coronary heart disease
46. Nicotine addiction in Britain
47. Efficacy of nicotine nasal spray in smoking cessation: A placebo-controlled, double-blind trial
48. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
49. Nicotine replacement therapy for smoking cessation
50. Randomized controlled trial of nasal nicotine spray in smoking cessation
51. The Health Benefits of Smoking Cessation: A Report of the Surgeon General
52. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases
53. Smoking and plasma fibrinogen
54. Nicotine replacement therapy for patients with coronary artery disease
55. Leukocyte count, smoking and myocardial infarction
56. Dose-related cardiovascular and endocrine effects of transdermal nicotine